Connect with us

IT Industry

LexaGene Announces its Second Hemp-Cannabis Reference Testing Laboratory as a Beta Test Site

GlobeNewswire

Published

on

Reading Time: 3 minutes

BEVERLY, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene”) or the (“Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today plans to place its LX Analyzer beta unit into ProVerde Laboratories, Inc. (“ProVerde”), one of the largest hemp-cannabis testing reference laboratories in Massachusetts.

ProVerde Laboratories is one of three independent laboratories accredited by the state of Massachusetts to test hemp and cannabis products for contaminants such as pesticides and pathogens including bacteria, mold, or other dangerous microorganisms. Their testing capabilities are described in this video

ProVerde currently cultures samples overnight, followed by processing steps that include using an automated single-target immunoassay analyzer to identify pathogenic organisms as well as starting a second culture to enumerate indicator species.  The process nominally takes 3 days, and ProVerde is looking for faster turn-around times.  For this reason, ProVerde is interested in testing LexaGene’s analyzer, which is designed to screen for multiple pathogenic organisms at once and provide quantitation of indicator organisms in just 1 hour.  For the beta test trial, which is scheduled to start next week, ProVerde will use LexaGene’s genetic analyzer to detect and quantify pathogenic E. coli, Salmonella, and the toxic fungus, Aspergillus niger

“In the United States, the standards for hemp and cannabis testing are currently all over the map, as different states have different regulations.  ProVerde is active and vocal in promoting the benefits of uniform testing requirements across all the states,” said Dr. Christopher Hudalla, ProVerde’s Founder and Chief Scientific Officer. “Over the past several years, we have worked with a number of innovative companies to help them develop, refine and validate their equipment, processes and products for the cannabis and hemp testing markets.  It’s exciting to work with LexaGene and their new rapid detection platform which has the potential to make an impact on the testing demands of these industries.”

As the use of cannabis and hemp products for medicinal purposes increases, so does the opportunity for LexaGene to provide its open-access instrument for use in testing laboratories to enable screening for pathogens that affect human health. 

“This is now our second beta placement in a hemp-cannabis testing reference laboratory,” said Dr. Jack Regan, LexaGene’s CEO and Founder. “We strongly believe the LX technology will be revolutionary for the hemp and cannabis industry as it will help prevent the spread of disease and can be used to ensure safer products for consumption.”

To be added to the LexaGene email distribution list, please subscribe on the Company website.

About LexaGene Holdings Inc.
LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID, and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

About ProVerde Laboratories

ProVerde Laboratories, Inc. is a Massachusetts based laboratory offering analytical testing and consulting services for a wide variety of markets including the marijuana and hemp segment. Available services utilize leading-edge technologies to yield the most reliable analytical results available, while maintaining an environmentally friendly, green approach.

Media Contacts
Nicole Ridgedale
Director of Corporate Marketing, LexaGene
800.215.1824 ext 206
nridgedale@lexagene.com

Investor Relations
Jay Adelaar
Vice President of Capital Markets, LexaGene
800.215.1824 ext 207
jadelaar@lexagene.com

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

IT Industry

IDEX begins deliveries of its dual-interface sensor to world class electronics manufacturer

GlobeNewswire

Published

on

Reading Time: 1 minute

Oslo, Norway, 15 October 2019: IDEX Biometrics ASA, a leading provider of advanced fingerprint identification and authentication solutions, has received a purchase order and initiated production ramp preparations to fulfill a multi-year order commitment signed with a leading provider of global financial news and IT services, as announced in April this year.

As part of this multimillion-dollar commitment IDEX is supplying its dual-interface sensors to one of the world’s largest electronics manufacturing service companies in order to qualify their manufacturing process; a critical step in any ramp-up process.

Stan Swearingen, CEO of IDEX Biometrics comments: “This is an exciting time for IDEX as we gear up volume production with our partners in what will be a cutting-edge, secure access solution. We now expect a regular flow of purchase orders from this customer and look forward to being an integral part of the rollout of their enhanced biometric security solutions”.

For further information contact:
Stuart Hunt, Head of Investor Relations & Communications
+44 (0)1276 534 632

About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX) is the leading provider of fingerprint identification technologies offering simple, secure and personal authentication for all. We help people make payments, prove their identity, gain access to information, unlock devices or gain admittance to buildings with the touch of a finger. We invent, engineer and commercialize these secure, yet incredibly user-friendly solutions. Our total addressable market represents a fast-growing multi-billion-unit opportunity.

For more information, visit www.idexbiometrics.com and follow @IDEXBiometrics

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Continue Reading

IT Industry

Global e∙dentity™ files its third formal USPTO 37CFR1.290 request in six months against Apple AAPL (NASDAQ)

GlobeNewswire

Published

on

Reading Time: 1 minute

WILMINGTON, Del., Oct. 15, 2019 (GLOBE NEWSWIRE) — Global e∙dentity™, founded by Robert Adams, U.S. Navy veteran who along with the most amazing engineers & team, have developed and patented the next generation of identity protocol methods, has now filed its third 37CFR1.290 request with the USPTO within in six months against Apple; the formal third-party review request with the USPTO is in opposition to Apple newest patent application 16/262032 published on September 12, 2019. Adams stated that Global e∙dentity™ had “no choice, and once again, file a new third-party action with the USPTO in response to Apple’s latest published patent application.”  USPTO new third party filing is noted on the Global e·dentity™ website: https://www.globaledentity.com/third-party-review-uspto3/

Global e∙dentity™ was featured on Featured on KRON4 — San Francisco Bay Area’s Local TV www.globaledentity.com/2019/06/22/kron4-apple-intellectual-property-theft-and-patent-violations with regards the first of two third-party actions with the USPTO against Apple.  Adams continued, “We are indeed flattered that Apple has now filed, not one, not two, but now a third patent application based on our already patented technology 10,135,822 Biometric authentication of individuals utilizing characteristics of bone and blood vessel structures and its continuation patents.   Having said that, the key question remains: Why did Apple fail to inform the USPTO they had in their possession per their request, all of our trade secrets and provisional patent as early as March/April 2017 when negotiations started between representatives of Apple and Global e∙dentity?”

Global e·dentity™, is young well-funded tech start-up company with national security applications in mind; providing secure multi-factor biometric and digital identity solutions. For more information, visit www.globaledentity.com. Global e·dentity™ and product are either registered trademarks or trademarks of You are the ID ™ LLC in the United States and/or other countries.

For more information, press only: Sophia Miller  sophiam@globaledentity.com

Continue Reading

IT Industry

Digia Plc will publish its business review January-September 2019 on October 31, 2019

GlobeNewswire

Published

on

Reading Time: 1 minute

Digia Plc
Investor News
15 October 2019 at 09:00 am


Digia Plc will publish its business review January-September 2019 on Thursday 31 October at 8:00 am EET (GMT +2). After the publishing the report is available on: https://digia.com/en/investors/stock-exchange-releases/.

Timo Levoranta, President & CEO, and Kristiina Simola, CFO, will present the financial results in Finnish at an analyst and press conference in Helsinki on Thursday, October 31, 2019 at 11.00 am (EET). The conference will take place at Business Meeting Park in Helsinki (address: Forum, Mannerheimintie 20 B, 6th floor. Entrance from the glass corner of Mannerheimintie and Simonkatu).

The material and presentation for the event will be available from 11 am on October 31, 2019 in the Investors section of the company’s website: www.digia.com/en/investors/reports-and-presentations.

Digia Oyj
Timo Levoranta, CEO


Additional information:

Kristiina Simola, CFO, tel. +358 40 756 3132

Distribution:
Nasdaq Helsinki
Key media
digia.com

Digia is a software and service company that helps its customers renew themselves digitally. There are more than 1,200 of us working at Digia. Our roots are in Finland and we operate with our customers in Finland and abroad. world. We are building a world in which digitalisation makes a difference. Digia net sales were EUR 112.1 million in 2018. The company is listed on Nasdaq Helsinki (DIGIA). digia.com

Continue Reading

Font Resizer

Subscribe to PICANTE via Email

Enter your email address to subscribe to PICANTE and receive notifications of new posts by email.

Follow us on Facebook

Read more from our authors

Follow our Tweets

Trending

Please turn AdBlock off